Desmethyl cariprazine prodrug - Abbvie
Alternative Names: ABBV-932; RGH-932Latest Information Update: 30 Jan 2026
At a glance
- Originator Gedeon Richter
- Developer AbbVie; Gedeon Richter
- Class Antidepressants; Anxiolytics; Mood stabilisers; Small molecules
- Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bipolar depression; Bipolar disorders; Generalised anxiety disorder
- Phase I Unspecified
Most Recent Events
- 10 Dec 2025 AbbVie completes a phase II clinical trials in Bipolar depression in Puerto Rico, Japan (PO) (NCT06605599)
- 30 Sep 2025 Phase-II clinical trials in Bipolar disorders in USA (PO) (NCT07220460)
- 21 Aug 2025 AbbVie initiates a phase-I pharmacokinetics trial (In volunteers) in China (PO, Capsule) (NCT07024797)